Marta Maskey-Warzęchowska, Krzysztof Karwat, Benedykt Szczepankiewicz, Renata Langfort, Małgorzata Szołkowska, Ryszarda Chazan
{"title":"Leflunomide-induced acute interstitial pneumonia in a patient treated for rheumatoid arthritis.","authors":"Marta Maskey-Warzęchowska, Krzysztof Karwat, Benedykt Szczepankiewicz, Renata Langfort, Małgorzata Szołkowska, Ryszarda Chazan","doi":"10.5603/PiAP.2015.0007","DOIUrl":null,"url":null,"abstract":"<p><p>Leflunomide is a disease-modifying anti-rheumatic drug that is used in patients with rheumatoid arthritis (RA), who do not respond well to standard RA treatment. Leflunomide therapy may, however, be related with significant pulmonary complications in predisposed individuals. We present a patient with RA treated with leflunomide, in whom leflunomide lung injury had a fatal outcome. Potential risk factors for pulmonary complications of leflunomide treatment and the management of patients with leflunomide lung injury are discussed. </p>","PeriodicalId":20258,"journal":{"name":"Pneumonologia i alergologia polska","volume":"83 1","pages":"50-4"},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pneumonologia i alergologia polska","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/PiAP.2015.0007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Leflunomide is a disease-modifying anti-rheumatic drug that is used in patients with rheumatoid arthritis (RA), who do not respond well to standard RA treatment. Leflunomide therapy may, however, be related with significant pulmonary complications in predisposed individuals. We present a patient with RA treated with leflunomide, in whom leflunomide lung injury had a fatal outcome. Potential risk factors for pulmonary complications of leflunomide treatment and the management of patients with leflunomide lung injury are discussed.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
